Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TempraMed TechnologiesFRA:9DY +1.40%10 PS Ratio is 20.71 as of Jul. 22, 2026, which is 30% below its 10-year median of 29.78. GuruFocus rates FRA:9DY with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, TempraMed Technologies ranks worse than 91.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TempraMed Technologies's share price is €0.29.
TempraMed Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.01. Hence, TempraMed Technologies's PS Ratio for today is 20.71.
Good Sign:
TempraMed Technologies Ltd stock PS Ratio (=22.27) is close to 1-year low of 22.27.
The historical rank and industry rank for TempraMed Technologies's PS Ratio or its related term are showing as below:
FRA:9DY'
s PS Ratio Range Over the Past 10 Years
Min: 22.27 Med: 29.78 Max: 50
Current: 22.58
During the past 3 years, TempraMed Technologies's highest PS Ratio was 50.00. The lowest was 22.27. And the median was 29.78.
FRA:9DY's PS Ratio is ranked worse than 91.92% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.82
vs FRA:9DY: 22.58
TempraMed Technologies (FRA:9DY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TempraMed Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TempraMed Technologies PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TempraMed Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where TempraMed Technologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TempraMed Technologies's Share Price of today is €0.29. TempraMed Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TempraMed Technologies (FRA:9DY) has a PS Ratio of 20.71 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TempraMed Technologies and its competitors. This is 30% below median its historical median of 29.78. Over the past decade, TempraMed Technologies' PS Ratio has ranged from 22.27 to 50.00. According to the industry distribution chart, TempraMed Technologies ranks #739 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 91.9%.
Is TempraMed Technologies' PS Ratio too high?
TempraMed Technologies' current PS Ratio of 20.71 is 30% below median its 10-year median of 29.78. Over the past 10 years, this metric has ranged from a low of 22.27 to a high of 50.00. The Medical Devices & Instruments industry median PS Ratio is 2.82. TempraMed Technologies' value of 20.71 is 634.4% above this industry median. Based on the distribution chart, TempraMed Technologies ranks #739 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TempraMed Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, TempraMed Technologies ranks #739 out of 804 companies for PS Ratio. This places TempraMed Technologies in the lower half of its industry. The industry median PS Ratio is 2.82. TempraMed Technologies' value of 20.71 is 634.4% above this benchmark. Historically, TempraMed Technologies' own PS Ratio has ranged from 22.27 to 50.00 over the past decade. While the company's 10-year median is 29.78 vs. the industry median of 2.82, TempraMed Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.82, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TempraMed Technologies's current PS Ratio of 20.71 is 634.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TempraMed Technologies and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current PS Ratio is 20.71, which is 30% below median its own 10-year median of 29.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current PS Ratio of 20.71. The current PS Ratio is 20.71, which is 30% below median its 10-year median of 29.78 and 634.4% above the Medical Devices & Instruments industry median of 2.82. TempraMed Technologies' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current PS Ratio is 20.71 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
10GF Score
Get the complete analysis for FRA:9DY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9DY has been successfully added to your 
